Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam semper velit interdum mi sodales malesuada. Fusce eleifend ex id fringilla mattis. Nam accumsan, nisi in interdum tempus, leo odio venenatis nunc, vitae euismod tortor sem vitae nibh. Ut quis lorem quis diam pulvinar sollicitudin. Ut eu magna quis tellus suscipit egestas. Vestibulum cursus cursus ante, et semper augue faucibus in. In suscipit, magna eget ultrices convallis, risus dolor cursus quam, vitae rhoncus orci metus id mi. Sed pretium nibh in hendrerit ornare. Praesent facilisis volutpat tortor eu rutrum. Proin eget augue quam.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam semper velit interdum mi sodales malesuada. Fusce eleifend ex id fringilla mattis. Nam accumsan, nisi in interdum tempus, leo odio venenatis nunc, vitae euismod tortor sem vitae nibh. Ut quis lorem quis diam pulvinar sollicitudin. Ut eu magna quis tellus suscipit egestas. Vestibulum cursus cursus ante, et semper augue faucibus in. In suscipit, magna eget ultrices convallis, risus dolor cursus quam, vitae rhoncus orci metus id mi. Sed pretium nibh in hendrerit ornare. Praesent facilisis volutpat tortor eu rutrum. Proin eget augue quam.
Focus Care Pharmaceuticals and Axxelent Pharma Science Forge Strategic Collaboration for Generic Product Development and Marketing in Dutch and European Markets.
Zaandam, Netherlands, May 27, 2024 – Focus Care Pharmaceuticals (“Focus Care”), a rapidly growing and quality-centric generic pharmaceutical company based in Zaandam, Netherlands, and Axxelent Pharma Science (“Axxelent”), a research-driven pharmaceutical firm headquartered in Chennai, India, have entered into a strategic partnership. This collaboration aims to develop and market generic products for the Dutch and broader European markets.
Focus Care is dedicated to delivering affordable, safe, and effective medications to the Dutch market. Axxelent, with its focus on the development and manufacturing of complex oral solid dosage forms, oral liquids, topical dosage forms, ophthalmic products, and injectables for regulated markets, prides itself on its commitment to collaboration, value, and compliance.
“In this new and thriving phase at Focus Care, we are thrilled to partner with Axxelent, a company that shares our core values. While our primary market is the Netherlands, we are also exploring the potential to expand our reach across Europe,” said Maurits Haasnoot, Owner and CEO of Focus Care Pharmaceuticals.
Jitesh Devendra, Co-Founder and Chairman of Axxelent, echoed this enthusiasm: “Focus Care aims to be a leading generic player in the Dutch and possibly European market, and Axxelent strives to be a reliable partner for the development and supply of products. Our shared visions make this collaboration complementary and synergistic.”
Both companies believe that their combined efforts will yield greater results than they could achieve individually. This groundbreaking partnership marks the start of an exciting journey, with both firms eager to leverage their expertise to develop high-quality, affordable, and accessible products for their customers.
For more information on Focus Care, please visit focuscare.nl.
For more information on Axxelent Pharma Science, please visit axxelent.com.
AeroChamber2go™ voor onderweg, in aanvulling op de vertrouwde AeroChamber Plus® Flow-Vu® voor thuis.
Het artikel van Prof. dr. P.N.R. (Richard) Dekhuijzen en Dr. P. (Paul) Hagedoorn, in het Pharmaceutisch Weekblad van 13 november 2020 bevestigt wederom dat voorzetkamers niet één op één uitwisselbaar zijn en daarmee een bewuste keuze voor AeroChamber Plus® Flow-Vu® kan worden gemaakt.
Hele artikel nog eens doorlezen?
Klik op de button voor de download